Description
+ Include: 22 videos, size: 5 GB
+ Target Audience: hematologists, medical oncologists, pharmacists
+ Sample video: contact me for sample video
+ Information:
Treatment options for relapsed/refractory (advanced) hematologic malignancies have progressed rapidly in only the last decade. Development of revolutionary treatment options, including CAR T-cell therapy, novel immunotherapies, and novel chemotherapeutic agents has only accelerated since the first product targeting CD19 was developed in 2003. These developments provide excellent opportunities for patients, and with opportunities arrive challenges for clinicians in maintaining optimal approaches to care. To address the educational need the 2nd Midwest Cellular Conference: Treatment Options for Advanced Hematologic Malignancies is planned . This activity will engage an interprofessional audience of learners with important updates in hematologic oncology that are provided at the annual Transplantation and Cellular Therapy (TCT) meeting organized in February 2022, and at the American Society of Hematology (ASH) in December 2021. As an added benefit, a half-day pre-conference entitled Women in Cell Therapy will be provided.
This program is designed to meet the educational needs of hematologists, medical oncologists, pharmacists, fellows and residents, APP’s, oncology nurses and other healthcare professionals committed to the field of cellular treatment options for advanced hematologic malignancies.
LEARNING OBJECTIVES
Following participation in this activity, learners will:
- Discuss individualized treatment options for high-risk patients with diffuse large B-cell lymphoma (DLBCL), Hodgkins lymphoma (HL), non-Hodgkin Lymphoma (NHL), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
- Include autologous or allogeneic HCT and/or CAR T-cell therapy in treatment plans for patients with various refractory (advanced) hematologic malignancies.
- Manage potential complications resulting from autologous or allogeneic HCT and/or CAR T-cell therapy.
- Utilize newer chemotherapeutic treatment options in conjunction with HCT and CAR T-cell therapy for patients with various refractory (advanced) hematologic malignancies.
- Discuss the role of gender in the management and treatment of various hematologic conditions
+ Topics:
Alternative Allogeneic Transplant Donors- How These Are Changing the Landscape.mp4
APPs in Cellular Therapy.mp4
CAR T-Cells in Pediatrics.mp4
Cardio-Oncology in Cell Therapy.mp4
Failure After CAR T-Cell Therapy in Lymphoma- What To Do Next.mp4
Gene Therapy in Sickle Cell Disease.mp4
HaploSCT- Choosing an Optimal Donor and Novel Strategies to Mitigate Post HaploSCT Relapse and Improve Immune Reconstitution.mp4
High-Risk Myeloma- Failures and Future Directions.mp4
Hodgkin Lymphoma- Managing Brentuximab Vedotin CPI Dual Refractory Patients.mp4
Immunotherapy in MM- Beyond CAR-T.mp4
Improving Neutropenic Fever Strategies.mp4
Mantle Cell Lymphoma Management After AutoHCT Relapse.mp4
Myelofibrosis- Novel Agents and HCT.mp4
Novel Agents for MDS.mp4
Novel Therapies for Relapsed AML.mp4
Pharmacy in Cellular Therapy.mp4
Post-HCT Relapse Prevention in Myeloid Malignancies.mp4
RR Follicular Lymphoma- Novel Agent, Transplant, or CAR T-Cells.mp4
Thrombotic Microangiopathies- Modern Diagnosis and Treatments.mp4
Update on CAR-T Therapy for Multiple Myeloma.mp4
Upfront Autologous Transplant in Multiple Myeloma.mp4
Work-Life Balance- Avoiding Burnout.mp4
Reviews
There are no reviews yet.